← Leaderboards
Weiquan (wendy) Zhu
University Of Utah
$2,932,948
Attributed
$3,817,146
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $707.8K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,817,146 · 3
By mechanism
R01$3,817,146 · 3
Top collaborators
- Mary Elizabeth Ruth Hartnett3 shared
Most similar at University Of Utah
Same institution · by research overlap
- Allie H. Grossmann$3,010,476
- Dean Yaw Li$21,127,919
- Jae Hyuk Yoo$1,563,438
- Bradley Katz$681,395
- Shannon J Odelberg$4,968,511
Others in their field
Top investigators on “Endothelial Cells”
- Keri Hammel · The Emmes Company, Llc$41,089,609
- Martin Friedlander · Scripps Research Institute$38,298,285
- Michael Simons · Yale University$37,176,481
- Ajit P Varki · University Of California San Diego$34,208,221
- Joseph C Wu · Stanford University$33,648,524
- Jan E Schnitzer · Sidney Kimmel Cancer Center$31,414,677
Research focus
Endothelial CellsBlood VesselsMolecularProteinsCellsPharmaceutical PreparationsTnf GenePermeabilityInflammatoryFutureSignal PathwayKnockout MiceMouse ModelMonomeric Gtp-Binding ProteinsRetinal NeovascularizationNeovascularRetinaBlindnessExudative Age-Related Macular DegenerationGrowthPublishingNeovascularizationResponseVascular Diseases
Grant awards (9)
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration$523,346
R01 · FY2025 · EY · contact PI
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration$615,699
R01 · FY2024 · EY · contact PI
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration$629,351
R01 · FY2023 · EY · contact PI
Targeting ARF6, A Convergence Point For Multiple Pathways of Diabetic Retinopathy$335,250
R01 · FY2019 · EY · contact PI
Targeting ARF6, A Convergence Point For Multiple Pathways of Diabetic Retinopathy$335,250
R01 · FY2018 · EY · contact PI
Endothelial Toll-Like Receptor Signaling and Inflammation$372,500
R01 · FY2017 · HL · contact PI
Targeting ARF6, A Convergence Point For Multiple Pathways of Diabetic Retinopathy$335,250
R01 · FY2017 · EY · contact PI
Targeting ARF6, A Convergence Point For Multiple Pathways of Diabetic Retinopathy$335,250
R01 · FY2016 · EY · contact PI
Targeting ARF6, A Convergence Point For Multiple Pathways of Diabetic Retinopathy$335,250
R01 · FY2015 · EY · contact PI